Truscreen (ASX:TRU) is gaining momentum in a diverse range of jurisdictions

We spoke to Marty Dillon, CEO of Truscreen (ASX:TRU) about the progress TRU has made in getting its TruScreen Cervical Cancer Screening Device to be used in multiple emerging markets. Recent launches of approvals in places as diverse as Vietnam, Indonesia and Uzbekistan bode well for future revenues given the scale of potential screening programmes and the obvious advantages of Truscreen's device.